#ID,Chromosome,ChromosomePosition,Chr:ChrPos,Ref,RefAA,Alt,AltAA,Type,Coverage,Pathogenicity,PathogenicityStatus,Gene,GeneStrand,ExonNumber,Transcript,Protein,CodingBase,CodonPosition,AAPosition,HGVSGenomic,HGVSCodingTranscript,HGVSCoding,HGVSTranslationProtein,HGVSProtein,PanelGroup,comment_date,comment,variant_id
49418,1,9782378,1:9782378,G,Gly,A,Ser,missense,1838,Unknown significance,Pending,PIK3CD,+,18,NM_005026.3,NP_005017.3,2311,1,771,g.9782378G>A,NM_005026.3,c.2311G>A,NP_005017.3,p.Gly771Ser,Heme-STAMP,1/3/24 17:30,"2024/01/03: gnomAD: South Asian maf=0.000360, Other maf=0.000165, Latino maf=0.000029, Total maf=0.000056. ClinVar: Conflicting interpretations of pathogenicity, 1 star, 2 submissions. Not in JaxCKB. No functional data in published literature. OncoKB: Unknown.",
49417,13,32913512,13:32913512,A,Ser,G,Gly,missense,1044,Unknown significance,Pending,BRCA2,+,11,NM_000059.3,NP_000050.2,5020,1,1674,g.32913512A>G,NM_000059.3,c.5020A>G,NP_000050.2,p.Ser1674Gly,Capp-Seq,1/3/24 6:56,"2024/01/02: gnomAD: African maf=0.000458, Latino maf=0.000125, European maf=0.000000, Total maf=0.000056. ClinVar: Conflicting interpretations of pathogenicity, 1 star, 13 submissions. Not in JaxCKB. No functional data in published literature. OncoKB: Unknown.",
49416,13,32912670,13:32912670,C,Ala,T,Val,missense,1188,Unknown significance,Pending,BRCA2,+,11,NM_000059.3,NP_000050.2,4178,2,1393,g.32912670C>T,NM_000059.3,c.4178C>T,NP_000050.2,p.Ala1393Val,Capp-Seq,1/3/24 6:56,"2024/01/02: gnomAD: African maf=0.000064, European maf=0.000000, Finnish maf=0.000000, Total maf=0.000004. ClinVar: Conflicting interpretations of pathogenicity, 1 star, 9 submissions. Not in JaxCKB. No functional data in published literature. OncoKB: Unknown.",
49415,12,69233344,12:69233344,A,Pro,G,Pro,synonymous,1403,Unknown,Pending,MDM2,+,11,NM_002392.5,NP_002383.2,1209,3,403,g.69233344A>G,NM_002392.5,c.1209A>G,NP_002383.2,p.Pro403=,Capp-Seq,,,
49414,8,67485719,8:67485719,A,Asn,G,Ser,missense,742,Unknown significance,Pending,MYBL1,-,11,NM_001080416.2,NP_001073885.1,1493,2,498,g.67485719T>C,NM_001080416.2,c.1493A>G,NP_001073885.1,p.Asn498Ser,Capp-Seq,1/3/24 6:55,"2024/01/02: gnomAD: African maf=0.000416, Latino maf=0.000060, European maf=0.000000, Total maf=0.000044. ClinVar: Uncertain significance, 1 star, 1 submission. Not in JaxCKB. No functional data in published literature. OncoKB: Unknown.",
49413,3,178937422,3:178937422,T,Cys,C,Arg,missense,806,Likely Pathogenic,Pending,PIK3CA,+,12,NM_006218.2,NP_006209.2,1810,1,604,g.178937422T>C,NM_006218.2,c.1810T>C,NP_006209.2,p.Cys604Arg,Capp-Seq,1/3/24 6:41,"The p.Cys604Arg (c.1810T>C, p.C604R) variant in the PIK3CA gene results in a substitution of an arginine for the wild-type cysteine at codon 604 and is located in the accessory domain of the protein. Expression of this mutation in Ba/F3 and MCF10A cell lines demonstrated that it is activating as measured by increased proliferation in the absence of growth factors compared to wildtype PIK3CA (PMID: 29533785). This variant has been recurrently identified in patients with colorectal adenocarcinoma (PMID: 27149842, PMID: 25344691). Tumor-associated PIK3CA mutations occur most commonly in the helical and kinase domains, and are associated with increased kinase activity and oncogenic transformation in vitro. They are found in approximately 30% of breast cancers (more commonly in estrogen/progesterone receptor positive and HER2 positive than triple negative tumors). PIK3CA mutations are also seen in some gynecologic malignancies, 10-30% of colorectal carcinomas, 10% of squamous non-small cell lung cancers, and fewer lung adenocarcinomas. In addition, activating mutations in the helical and kinase domains of PIK3CA are reported in lymphatic and venous malformations. mTOR inhibitors, such as sirolimus, are effective therapeutic options for patients with extensive vascular malformations (PMID 30373605, 29924669). References: PMID 22330809, 19671852, 22271473, 23936763, 18676830, 23612454, 17376864, 26655088, 21266528, 26492180.",
49412,3,178916944,3:178916944,A,Lys,G,Glu,missense,855,Likely Pathogenic,Pending,PIK3CA,+,2,NM_006218.2,NP_006209.2,331,1,111,g.178916944A>G,NM_006218.2,c.331A>G,NP_006209.2,p.Lys111Glu,Capp-Seq,1/3/24 6:53,"The p.Lys111Glu (c.331A>G, p.K111E) variant in the PIK3CA gene results in a substitution of a glutamic acid for the wild-type lysine at codon 111 and is located in the protein's linker region within the N-terminus. This mutation has been found to occur in endometrial and breast cancers (PMID: 18074223, 22949682, 21266528). Expression of this mutation in Ba/F3 and MCF10A cell lines demonstrated that it is activating as measured by increased downstream pathway activation and proliferation in the absence of growth factors compared to wildtype PIK3CA (PMID: 29533785, 18074223, 22949682, 21266528). Tumor-associated PIK3CA mutations occur most commonly in the helical and kinase domains, and are associated with increased kinase activity and oncogenic transformation in vitro. They are found in approximately 30% of breast cancers (more commonly in estrogen/progesterone receptor positive and HER2 positive than triple negative tumors). PIK3CA mutations are also seen in some gynecologic malignancies, 10-30% of colorectal carcinomas, 10% of squamous non-small cell lung cancers, and fewer lung adenocarcinomas. In addition, activating mutations in the helical and kinase domains of PIK3CA are reported in lymphatic and venous malformations. mTOR inhibitors, such as sirolimus, are effective therapeutic options for patients with extensive vascular malformations (PMID 30373605, 29924669). References: PMID 22330809, 19671852, 22271473, 23936763, 18676830, 23612454, 17376864, 26655088, 21266528, 26492180.",
49411,17,7579699,17:7579699,G,N/A,T,N/A,splice-site,182,Likely Pathogenic,Pending,TP53,-,intron,NM_000546.5,NP_000537.3,N/A,N/A,N/A,g.7579699C>A,NM_000546.5,c.96+1G>T,N/A,N/A,Capp-Seq,1/3/24 4:52," The c.96+1G>T (p.?) variant in the TP53 gene results in disruption of a canonical splice site. Experimental studies of the novel transcript are not available. However, this mutation may result in exon skipping, retention of intronic regions in the transcript, and/or a premature stop codon. TP53 is the most commonly mutated gene in human cancer and mutations are typically associated with poor prognosis. References: PMID 23263379, 22713868, 21045690, 29979965. ",
49410,12,133245468,12:133245468,G,Glu,A,Lys,missense,1232,Unknown significance,Pending,POLE,-,17,NM_006231.2,NP_006222.2,1852,1,618,g.133245468C>T,NM_006231.2,c.1852G>A,NP_006222.2,p.Glu618Lys,Capp-Seq,1/3/24 4:38,"2024/01/02: Not in gnomAD. ClinVar: Uncertain significance, 2 stars, 4 submissions. Not in JaxCKB. No functional data in published literature. OncoKB: Unknown.",
49409,11,125495711,11:125495711,C,N/A,G,N/A,N/A,728,Unknown,Pending,CHEK1,+,5' UTR,NM_001274.5,NP_001265.2,N/A,N/A,N/A,g.125495711C>G,NM_001114121.2,c.-217C>G,N/A,N/A,Capp-Seq,1/3/24 4:36,"2024/01/02: Intronic. gnomAD: East Asian maf=0.000096, European maf=0.000000, Finnish maf=0.000000, Total maf=0.000008. Not in ClinVar. Not in JaxCKB. No functional data in published literature. OncoKB: Unknown.",
49408,9,139402812,9:139402812,C,Ser,T,Leu,missense,1123,Unknown significance,Pending,NOTCH1,-,20,NM_017617.3,NP_060087.3,3197,2,1066,g.139402812G>A,NM_017617.3,c.3197C>T,NP_060087.3,p.Ser1066Leu,Capp-Seq,1/3/24 4:47,"2024/01/02: gnomAD: East Asian maf=0.000051, European maf=0.000016, Finnish maf=0.000000, Total maf=0.000011. Not in ClinVar. Not in JaxCKB. No functional data in published literature. OncoKB: Unknown.",
49407,2,141272338,2:141272338,C,Ser,T,Phe,missense,520,Unknown significance,Pending,LRP1B,-,51,NM_018557.2,NP_061027.2,8153,2,2718,g.141272338G>A,NM_018557.2,c.8153C>T,NP_061027.2,p.Ser2718Phe,Capp-Seq,1/3/24 4:45,2024/01/02: Not in gnomAD. Not in ClinVar. Not in JaxCKB. No functional data in published literature. OncoKB: Unknown.,
49406,2,29917727,2:29917727,A,Glu,G,Gly,missense,881,Unknown significance,Pending,ALK,-,3,NM_004304.4,NP_004295.2,941,2,314,g.29917727T>C,NM_004304.4,c.941A>G,NP_004295.2,p.Glu314Gly,Capp-Seq,1/3/24 4:46,"2024/01/02: gnomAD: East Asian maf=0.000598, European maf=0.000000, Finnish maf=0.000000, Total maf=0.000044. ClinVar: Uncertain significance, 1 star, 1 submission. Not in JaxCKB. No functional data in published literature. OncoKB: Unknown.",
49405,19,17954193,19:17954193,C,Ala,A,Asp,missense,517,Unknown significance,Pending,JAK3,-,4,NM_000215.3,NP_000206.2,416,2,139,g.17954193G>T,NM_000215.3,c.416C>A,NP_000206.2,p.Ala139Asp,Capp-Seq,1/3/24 2:13,"2024/01/02: gnomAD: East Asian maf=0.000062, European maf=0.000000, Finnish maf=0.000000, Total maf=0.000005. Not in ClinVar. Not in JaxCKB. No functional data in published literature. OncoKB: Unknown.",
49404,18,48604743,18:48604743,C,Pro,G,Arg,missense,626,Unknown significance,Pending,SMAD4,+,12,NM_005359.5,NP_005350.1,1565,2,522,g.48604743C>G,NM_005359.5,c.1565C>G,NP_005350.1,p.Pro522Arg,Capp-Seq,1/3/24 2:15,2024/01/02: Not in gnomAD. Not in ClinVar. Not in JaxCKB. No functional data in published literature. OncoKB: Unknown.,
49403,2,48030612,2:48030612,C,Arg,T,Cys,missense,911,Unknown significance,Pending,MSH6,+,5,NM_000179.2,NP_000170.1,3226,1,1076,g.48030612C>T,NM_000179.2,c.3226C>T,NP_000170.1,p.Arg1076Cys,Capp-Seq,1/3/24 2:12,"2024/01/02: gnomAD: East Asian maf=0.000272, South Asian maf=0.000163, African maf=0.000123, Total maf=0.000095. ClinVar: Likely pathogenic, 3 stars, 23 submissions. JaxCKB:MSH6 R1076C lies within the ATPase domain of the Msh6 protein (PMID: 17531815). R1076C has been identified in the scientific literature (PMID: 33422121, PMID: 22250089, PMID: 26832770), but has not been biochemically characterized and therefore, its effect on Msh6 protein function is unknown (PubMed, Jul 2023).",
49402,1,27023307,1:27023307,C,Ser,A,Ter,nonsense,788,Likely Pathogenic,Pending,ARID1A,+,1,NM_006015.4,NP_006006.3,413,2,138,g.27023307C>A,NM_006015.4,c.413C>A,NP_006006.3,p.Ser138Ter,Capp-Seq,1/3/24 2:04,"The p.Ser138Ter (c.413C>A, p.S138*) variant in the ARID1A gene results in a premature termination codon at amino acid position 138 and is predicted to result in loss-of-function. ARID1A promotes the formation of the SWI/SNF chromatin remodeling complex and functions as a tumor suppressor. Inactivating mutations in ARID1A are frequently observed in endometrial, bladder, and ovarian cancers. They have also been documented in gastric cancer and neuroblastoma, and rarely in other cancer types. References: PMID 21900401, 20942669, 20826764, 22037554, 21412130, 23202128. ",
49401,1,16460102,1:16460102,G,N/A,T,N/A,splice-site,491,Likely Pathogenic,Pending,EPHA2,-,intron,NM_004431.3,NP_004422.2,N/A,N/A,N/A,g.16460102C>A,NM_004431.3,c.1739-1G>T,N/A,N/A,Capp-Seq,1/3/24 2:04,"The c.1739-1G>T (p.?) variant in the EPHA2 gene results in disruption of a canonical splice site. Experimental studies of the novel transcript are not available. However, this mutation may result in exon skipping, retention of intronic regions in the transcript, and/or a premature stop codon, and is predicted to result in loss-of-function. EPHA2 encodes a receptor tyrosine kinase that is activated by ephrin ligands and appears to function as either an oncogene or tumor-suppressor depending on the tumor type. Mutations in EPHA2 have been identified across multiple cancer types. Limited evidence in a mouse model of lung cancer suggests that in the presence of an activating KRAS mutation, EPHA2 loss-of-function results in increased MAP kinase and hedgehog signaling, increased cell proliferation, and increased lung cancer tumorigenesis. References: PMID 19074825, 26542681.",
49400,20,57485065,20:57485065,A,Lys,T,Ile,missense,1730,Unknown significance,Pending,GNAS,+,11,NM_000516.4,NP_000507.1,2828,2,943,g.57485065A>T,NM_000516.4,c.899A>T,NP_000507.1,p.Lys300Ile,Capp-Seq,1/3/24 1:50,2024/01/02: Not in gnomAD. Not in ClinVar. Not in JaxCKB. No functional data in published literature. OncoKB: Unknown.,